DAX25.284 ±-0,0%Est506.138 -0,4%MSCI World4.343 -0,1%Top 10 Crypto7,9600 -7,6%Nas22.668 -0,9%Bitcoin56.669 +1,7%Euro1,1815 +0,1%Öl72,48 +2,2%Gold5.278 +1,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Siemens Energy ENER6Y Deutsche Telekom 555750 freenet A0Z2ZZ Netflix 552484 Bayer BAY001 DroneShield A2DMAA Allianz 840400 AIXTRON A0WMPJ RENK RENK73 Deutsche Bank 514000 E.ON ENAG99 Infineon 623100 Münchener Rückversicherungs-Gesellschaft 843002 PUMA 696960
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen schließen im Minus -- DAX geht stabil ins Wochenende -- Netflix steigt aus Warner-Bieterkampf aus -- BASF für 2026 vorsichtig -- Delivery Hero: Umsatz enttäuscht -- 1&1, AIXTRON im Fokus
Top News
Berkshire Hathaway-Aktie im Blick: So fiel die letzte Bilanz unter Leitung von Warren Buffett aus Berkshire Hathaway-Aktie im Blick: So fiel die letzte Bilanz unter Leitung von Warren Buffett aus
Lufthansa-Aktie: Flüge zu Zielen im Nahen Osten ausgesetzt Lufthansa-Aktie: Flüge zu Zielen im Nahen Osten ausgesetzt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Biogen Aktie

Kaufen
Verkaufen
Biogen Aktien-Sparplan
162,38 EUR +2,96 EUR +1,86 %
BMN
191,88 USD +3,96 USD +2,11 %
nachbörslich
BTT
Biogen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.23,37 Mrd. EUR

KGV20,02Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN789617

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS09062X1037

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBIIB

Biogen Aktien News

DatumMeistgelesen
PR NewswireEisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) ...
PR NewswireNew Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
PR NewswireEisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer'...
Wer­bungBiogen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireLEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
PR NewswireEisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
PR NewswireEisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disea...
PR Newswire/U P D A T E -- Eisai Inc./
PR NewswireFDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
PR NewswireTwo-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
PR NewswireNew Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
PR NewswireEarly Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
GlobeNewswireDapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
GlobeNewswireBiogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
GlobeNewswireBiogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
GlobeNewswireBiogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
GlobeNewswireBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
PR NewswireThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
GlobeNewswireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and N
GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
PR NewswireFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
GlobeNewswireFDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
GlobeNewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
PR NewswireFDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
PR Newswire"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
PR Newswire"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
GlobeNewswireDapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
PR NewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
GlobeNewswireEisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
GlobeNewswireEisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
GlobeNewswireBiogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
GlobeNewswireBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer
GlobeNewswireMichael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
GlobeNewswireBiogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswireBiogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
GlobeNewswireBiogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
GlobeNewswireBiogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
GlobeNewswireNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
GlobeNewswireUCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
GlobeNewswireBiogen Board Appoints Two New Independent Directors

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.